ATHA Share Price | Athira Pharma, Inc. Stock Analysis & Recommendation

Q: What does Athira Pharma, Inc. do?

Overview: Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) Market cap: USD 12.57 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.97 Return on Equity: -202.57% Price to Book: 0.34Contact Details: Address: 18706 North Creek Parkway, Suite 104, Box 352141 BOTHELL WA : 98011 Tel: 1 206 2218112 Fax: 1 302 6365454 Website: https://www.athira.com/

Q: Is Athira Pharma, Inc. technically bullish or bearish?

As of 9 June 2025, the technical trend has changed from mildly bullish to mildly bearish. The current technical stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish outlook and the weekly Bollinger Bands showing a mildly bearish trend. While the weekly MACD and KST are mildly bullish, they are overshadowed by the bearish signals from the daily moving averages and Bollinger Bands. The overall sentiment reflects a lack of strong bullish momentum, with the stock's performance significantly lagging behind the S&P 500 over various time frames.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

19.36 k

Shareholding (Dec 2025)

FII

1.62%

Held by 12 FIIs

DII

38.8%

Held by 14 DIIs

Promoter

46.71%

How big is Athira Pharma, Inc.?

22-Jun-2025

As of Jun 18, Athira Pharma, Inc. has a market capitalization of 12.57 million, with net sales of 0.00 million and a net profit of -79.74 million over the latest four quarters. Shareholder's funds are 44.84 million and total assets are 58.78 million.

View full answer

What does Athira Pharma, Inc. do?

22-Jun-2025

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and combat neurodegeneration. It has a market cap of $12.57 million and reported a net profit loss of $9 million as of March 2025.

View full answer

Who are in the management team of Athira Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Athira Pharma, Inc. includes Ms. Kelly Romano, who serves as a Director.

View full answer

Is Athira Pharma, Inc. technically bullish or bearish?

25-Jun-2025

As of June 9, 2025, the technical trend has shifted to mildly bearish, influenced by bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the weekly MACD and KST.

View full answer

Compare Athira Pharma, Inc. with Similar Stocks

NanoString Technologies, Inc.Affimed NV Turnstone Biologics Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 79 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.92

Return on Equity

-140.83%

Price to Book

2.93

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-83 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

119.21%

6 Months

160.78%

1 Year

276.59%

2 Years

-53.08%

3 Years

251.05%

4 Years

-89.09%

5 Years

-94.57%

Athira Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-204.80%

EBIT to Interest (avg)

-77.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.97

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.09%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.93

EV to EBIT

-1.37

EV to EBITDA

-1.40

EV to Capital Employed

26.76

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-1951.64%

ROE (Latest)

-140.83%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 10 Schemes (12.87%)

Foreign Institutions

Held by 12 Foreign Institutions (1.62%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -452.67% vs 45.05% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-15.30",
          "chgp": "33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-72.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-82.90",
          "val2": "-15.00",
          "chgp": "-452.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -8.98% vs 17.67% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.20",
          "val2": "-95.80",
          "chgp": "65.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-72.70",
          "val2": "-4.10",
          "chgp": "-1,673.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-105.60",
          "val2": "-96.90",
          "chgp": "-8.98%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.20

-15.30

33.33%

Interest

0.00

Exceptional Items

-72.70

0.00

Consolidate Net Profit

-82.90

-15.00

-452.67%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -452.67% vs 45.05% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-33.20

-95.80

65.34%

Interest

0.00

Exceptional Items

-72.70

-4.10

-1,673.17%

Consolidate Net Profit

-105.60

-96.90

-8.98%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -8.98% vs 17.67% in Dec 2024

All Annual Results

Company CV

About Athira Pharma, Inc.

Athira Pharma, Inc.

Pharmaceuticals & Biotechnology

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company’s pipeline is built from its drug discovery platform (ATH) platform, and consists of a series of small molecules that are designed to target either the central nervous system (CNS), by crossing the blood brain barrier (BBB), or the peripheral nervous system. The ATH platform utilizes proprietary technology to target and enhance the activity of a vital neuronal growth factor that promotes neuronal health and regeneration. The Company is developing ATH-1017, for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer’s disease (AD). ATH-1017 is designed to enhance neuronal health and promote regeneration, thereby improving symptoms in cognitively impaired subjects.

Company Coordinates

Company Details

18706 North Creek Parkway, Suite 104, Box 352141 BOTHELL WA : 98011

Tel: 1 206 2218112

https://www.athira.com/

Registrar Details